Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms
- PMID: 38687360
- DOI: 10.1007/s00213-024-06585-x
Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms
Abstract
Rationale: Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about these interactions is limited, as most clinical psilocybin research has prohibited concomittant SSRI use.
Objectives: We aimed to explore potential interactions between psilocybin and SSRIs by characterizing peoples' real-world experiences using psilocybin mushrooms and SSRIs together.
Methods: We conducted a systematic search of Reddit for posts describing psilocybin mushroom and SSRI coadministration. We identified 443 eligible posts and applied qualitative content analysis to each.
Results: 8% of posts reported negative physical or psychological effects resulting from coadministration. These included 13 reports that may reflect serotonin toxicity, and 1 concerning for a psychotic/manic episode. 54% of posts described reduced intensity of the acute psilocybin experience, but 39% reported unchanged intensity with SSRI coadministration.
Conclusions: Psilocybin's interactions with SSRIs are likely complex and may depend on multiple factors. Prospective studies are needed to evaluate whether psilocybin treatments are reliably safe and effective in the setting of SSRI use.
Keywords: Antidepressant; Drug-drug interactions; Psilocybin; Serotonin.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Similar articles
-
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.J Psychopharmacol. 2023 Jul;37(7):707-716. doi: 10.1177/02698811231179910. Epub 2023 Jun 8. J Psychopharmacol. 2023. PMID: 37291890
-
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.J Psychopharmacol. 2024 May;38(5):458-470. doi: 10.1177/02698811241237870. Epub 2024 Mar 22. J Psychopharmacol. 2024. PMID: 38520045 Free PMC article. Clinical Trial.
-
Psilocybin in pharmacotherapy of obsessive-compulsive disorder.Pharmacol Rep. 2024 Oct;76(5):911-925. doi: 10.1007/s43440-024-00633-1. Epub 2024 Aug 1. Pharmacol Rep. 2024. PMID: 39088105 Free PMC article. Review.
-
Psilocybin and hallucinogenic mushrooms.CNS Spectr. 2024 Dec;29(6):611-632. doi: 10.1017/S1092852924002487. Epub 2025 Jan 10. CNS Spectr. 2024. PMID: 39789676 Review.
-
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.Eur J Pharmacol. 2025 Mar 15;991:177304. doi: 10.1016/j.ejphar.2025.177304. Epub 2025 Jan 27. Eur J Pharmacol. 2025. PMID: 39864573
Cited by
-
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice.Int J Neuropsychopharmacol. 2025 Jun 6;28(6):pyaf035. doi: 10.1093/ijnp/pyaf035. Int J Neuropsychopharmacol. 2025. PMID: 40413648 Free PMC article.
-
Patient perceptions of lisdexamfetamine as a treatment for binge eating disorder: An exploratory qualitative and quantitative analysis.Psychiatry Res Commun. 2024 Dec;4(4):100195. doi: 10.1016/j.psycom.2024.100195. Epub 2024 Oct 5. Psychiatry Res Commun. 2024. PMID: 39664649 Free PMC article.
References
-
- Aday JS, Heifets BD, Pratscher SD et al (2022) Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. https://doi.org/10.1007/s00213-022-06123-7 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical